# Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation After Kidney Transplant

> **NCT00790439** · PHASE2 · WITHDRAWN · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)**

## Conditions studied

- Diabetes Mellitus, Type I

## Interventions

- **DRUG:** Low Molecular Weight Sulfated Dextran
- **DRUG:** Heparin
- **DRUG:** Mycophenolate Mofetil
- **DRUG:** Sirolimus
- **DRUG:** Tacrolimus
- **DRUG:** Cyclosporine
- **DRUG:** Daclizumab
- **DRUG:** Basiliximab
- **BIOLOGICAL:** Allogeneic Pancreatic Islet Cells

## Key facts

- **NCT ID:** NCT00790439
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2008-07
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Due to funding limitations
- **Last updated:** 2014-06-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00790439

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00790439, "Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation After Kidney Transplant". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT00790439. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*